Autor(es): Franco-Martinéz, Lorena ; Tecles, Fernando ; Torres-Cantero, A. ; Bernal, E. ; San-Lázaro, I. ; Alcaraz, M.J. ; Vicente-Romero, M.R. ; Lamy, Elsa ; Sánchez-Resalt, C. ; Rubio, Camila ; Tvarijonaviciute, Asta ; Martinez-Subiela, Silvia ; Ceron, Jose Joaquim
Data: 2022
Identificador Persistente: http://hdl.handle.net/10174/31832
Origem: Repositório Científico da Universidade de Évora
Assunto(s): Analytical validation; Assay; Biomarkers; COVID-19; Sars-CoV-2
Objectives The aim of the present study was to validate a commercially available automated assay for the measurement of total adenosine deaminase (tADA) and its isoenzymes (ADA1 and ADA2) in saliva in a fast and accurate way, and evaluate the possible changes of these analytes in individuals with SARS-CoV-2 infection. Methods The validation, in addition to the evaluation of precision and accuracy, included the analysis of the effects of the main procedures that are currently being used for SARS-CoV-2 inactivation in saliva and a pilot study to evaluate the possible changes in salivary tADA and isoenzymes in individuals infected with SARS-CoV-2. Results The automated assay proved to be accurate and precise, with intra- and inter-assay coefficients of variation below 8.2%, linearity under dilution linear regression with R2 close to 1, and recovery percentage between 80 and 120% in all cases. This assay was affected when the sample is treated with heat or SDS for virus inactivation but tolerated Triton X-100 and NP-40. Individuals with SARS-CoV-2 infection (n=71) and who recovered from infection (n=11) had higher mean values of activity of tADA and its isoenzymes than healthy individuals (n=35). Conclusions tADA and its isoenzymes ADA1 and ADA2 can be measured accurately and precisely in saliva samples in a rapid, economical, and reproducible way and can be analyzed after chemical inactivation with Triton X-100 and NP-40. Besides, the changes observed in tADA and isoenzymes in individuals with COVID-19 open the possibility of their potential use as non-invasive biomarkers in this disease.
